Walleye Capital’s Ginkgo Bioworks DNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2.03M Buy
158,116
+139,050
+729% +$1.13M ﹤0.01% 2805
2026
Q2
$189K Buy
+19,066
New +$159K ﹤0.01% 3540
2026
Q1
– Sell
-5,079
Closed -$42.2K – 4521
2025
Q4
$42.2K Buy
+5,079
New +$54.7K ﹤0.01% 4117
2025
Q1
– Sell
-266,129
Closed -$2.61M – 4418
2024
Q4
$2.61M Buy
266,129
+248,789
+1,435% +$2.13M 0.01% 1537
2024
Q3
$141K Buy
+17,340
New +$174K ﹤0.01% 4224

Other funds holding DNA

Walleye Capital's DNA Position: Q3 2026 in Review

Walleye Capital increased its Ginkgo Bioworks (DNA) stake by 729% in Q3 2026, buying an estimated $1.13M and bringing the position to 158,116 shares worth $2.03M. The position accounts for ﹤0.01% of the portfolio, ranked #2805.

Walleye Capital first reported a position in DNA in Q3 2024 and has held it in 5 quarters since. The position peaked at $2.61M in Q4 2024. 185 funds tracked by Wall St. Rank hold DNA as of Q3 2026.

  • Walleye Capital held 158,116 shares of Ginkgo Bioworks worth $2.03M as of Q3 2026.
  • Walleye Capital bought 139,050 Ginkgo Bioworks shares in Q3 2026, an estimated $1.13M.
  • Ginkgo Bioworks made up ﹤0.01% of Walleye Capital's portfolio in Q3 2026, its #2805 holding.
  • Walleye Capital first reported a position in Ginkgo Bioworks in Q3 2024 and has held it in 5 quarters since.
  • Walleye Capital's Ginkgo Bioworks position peaked at $2.61M in Q4 2024.
  • 185 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q3 2026.

Based on Walleye Capital's 13F filing for Q3 2026, filed 13 Nov 2026.